EVVA ALLEN: Open Payments
NPI 1457930430 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,036 in 47 payments from 12 companies in 2025. Trend: 2023 $2,632 · 2024 $2,238 · 2025 $1,036
Food & beverage: $936Education: $100
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 12 | $226 |
| Novartis Pharmaceuticals Corporation | 7 | $200 |
| ABBVIE INC. | 9 | $184 |
| Janssen Biotech, Inc. | 5 | $144 |
| PFIZER INC. | 5 | $77 |
| Amgen Inc. | 3 | $66 |
| Alexion Pharmaceuticals, Inc. | 1 | $32 |
| Genentech USA, Inc. | 1 | $25 |
| GlaxoSmithKline, LLC. | 1 | $23 |
| GENZYME CORPORATION | 1 | $23 |
Products named: Bimzelx, COSENTYX, TREMFYA, SKYRIZI, RINVOQ, XELJANZ, ULTOMIRIS, OTEZLA.
Industry payments across KY — which companies pay providers there.
